-
1
-
-
0030827498
-
A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
-
Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997 137 : 568 576.
-
(1997)
Br J Dermatol
, vol.137
, pp. 568-576
-
-
Meingassner, J.G.1
Grassberger, M.2
Fahrngruber, H.3
-
2
-
-
0032769627
-
A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
-
Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999 141 : 264 273.
-
(1999)
Br J Dermatol
, vol.141
, pp. 264-273
-
-
Grassberger, M.1
Baumruker, T.2
Enz, A.3
-
3
-
-
0033987120
-
Ascomycins: Promising agents for the treatment of inflammatory skin diseases
-
Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000 9 : 69 77.
-
(2000)
Expert Opin Invest Drugs
, vol.9
, pp. 69-77
-
-
Paul, C.1
Graeber, M.2
Stuetz, A.3
-
4
-
-
0001482634
-
SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin a and FK 506
-
Meingassner JG, Hiestand P, Bigaud M, et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506. J Invest Dermatol 2001 117 : 532.
-
(2001)
J Invest Dermatol
, vol.117
, pp. 532
-
-
Meingassner, J.G.1
Hiestand, P.2
Bigaud, M.3
-
5
-
-
0032896184
-
Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood
-
Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999 103 : 125 138.
-
(1999)
J Allergy Clin Immunol
, vol.103
, pp. 125-138
-
-
Williams, H.1
Robertson, C.2
Stewart, A.3
-
7
-
-
0001998488
-
Adverse side effects from the use of topical corticosteroids
-
In: Maibach, H.I., Surber, C. eds. Basel, Switzerland: Karger
-
Marks R. Adverse side effects from the use of topical corticosteroids. In : Maibach HI, Surber C eds. Topical corticosteroids. Basel, Switzerland : Karger, 1992 : 170 183.
-
(1992)
Topical Corticosteroids.
, pp. 170-183
-
-
Marks, R.1
-
8
-
-
0037508339
-
Adverse systemic effects of topical steroids
-
In: Maibach, H.I., Surber, C. eds. Basel, Switzerland: Karger
-
Robertson DB, Maibach HI. Adverse systemic effects of topical steroids. In : Maibach HI, Surber C eds. Topical corticosteroids. Basel, Switzerland : Karger, 1992 : 163 169.
-
(1992)
Topical Corticosteroids.
, pp. 163-169
-
-
Robertson, D.B.1
Maibach, H.I.2
-
9
-
-
0038183656
-
Topical corticosteroids in children: Local and systemic effects
-
In: Maibach, H.I., Surber, C. eds. Basel, Switzerland: Karger
-
Sillevis Smitt JH, Winterberg DH. Topical corticosteroids in children: local and systemic effects. In : Maibach HI, Surber C eds. Topical corticosteroids. Basel, Switzerland : Karger, 1992 : 196 209.
-
(1992)
Topical Corticosteroids.
, pp. 196-209
-
-
Sillevis Smitt, J.H.1
Winterberg, D.H.2
-
10
-
-
0030685730
-
Disease management of atopic dermatitis: A practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology, Work Group on Atopic Dermatitis
-
Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology, Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997 79 : 197 211.
-
(1997)
Ann Allergy Asthma Immunol
, vol.79
, pp. 197-211
-
-
Leung, D.Y.1
Hanifin, J.M.2
Charlesworth, E.N.3
-
11
-
-
3142636906
-
New concepts in atopic dermatitis
-
Boguniewicz M, Leung DYM. New concepts in atopic dermatitis. Compr Ther 1996 22 : 144 151.
-
(1996)
Compr Ther
, vol.22
, pp. 144-151
-
-
Boguniewicz, M.1
Leung, D.Y.M.2
-
12
-
-
0035034382
-
First experience of topical SDZ ASM 981 in children with atopic dermatitis
-
Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 144 : 781 787.
-
(2001)
Br J Dermatol
, vol.144
, pp. 781-787
-
-
Harper, J.1
Green, A.2
Scott, G.3
-
13
-
-
10744229850
-
Systemic exposure, tolerability and efficacy of pimecrolimus cream 1% in atopic dermatitis patients
-
Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 88 : 969 973.
-
(2003)
Arch Dis Child
, vol.88
, pp. 969-973
-
-
Allen, B.R.1
Lakhanpaul, M.2
Morris, A.3
-
14
-
-
0001128441
-
Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic eczema
-
Harper J, Lakhanpaul M, Wahn U, et al. Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic eczema. J Eur Acad Dermatol Venereol 2001 15 (Suppl. 2 S109.
-
(2001)
J Eur Acad Dermatol Venereol
, vol.15
, Issue.2 SUPPL.
-
-
Harper, J.1
Lakhanpaul, M.2
Wahn, U.3
-
15
-
-
0036169163
-
Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis
-
Van Leent EJM, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002 204 : 63 68.
-
(2002)
Dermatology
, vol.204
, pp. 63-68
-
-
Van Leent, E.J.M.1
Ebelin, M.E.2
Burtin, P.3
-
16
-
-
0001128440
-
Low blood concentrations of pimecrolimus (Elidel®, SDZ ASM 981) after topical treatment of adults with atopic eczema
-
Van Leent EJM, De Vries HJC, Scott G, et al. Low blood concentrations of pimecrolimus (Elidel®, SDZ ASM 981) after topical treatment of adults with atopic eczema. J Eur Acad Dermatol Venereol 2001 15 (Suppl. 2 S109.
-
(2001)
J Eur Acad Dermatol Venereol
, vol.15
, Issue.2 SUPPL.
-
-
Van Leent, E.J.M.1
De Vries, H.J.C.2
Scott, G.3
-
17
-
-
0025043171
-
Pathogenesis of eczema
-
Sampson HA. Pathogenesis of eczema. Clin Exp Allergy 1990 20 : 459 467.
-
(1990)
Clin Exp Allergy
, vol.20
, pp. 459-467
-
-
Sampson, H.A.1
-
18
-
-
85081438921
-
-
eds. 6th ed. Oxford: Blackwell Science
-
Champion RH, Burton JL, Burns DA, et al. eds. Rook/Wilkinson/Ebling, Textbook of Dermatology, 6th ed. Oxford : Blackwell Science, 1998 943.
-
(1998)
Rook/Wilkinson/Ebling, Textbook of Dermatology
, pp. 943
-
-
Champion, R.H.1
Burton, J.L.2
Burns, D.A.3
-
19
-
-
0028076776
-
The UK Working Party's diagnostic criteria for atopic dermatitis
-
Williams HC, Burney PG, Hay RJ, et al. The UK Working Party's diagnostic criteria for atopic dermatitis. Br J Dermatol 1994 31 : 383 396.
-
(1994)
Br J Dermatol
, vol.31
, pp. 383-396
-
-
Williams, H.C.1
Burney, P.G.2
Hay, R.J.3
-
20
-
-
0035136530
-
The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis EASI Evaluator Group
-
Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis EASI Evaluator Group. Exp Dermatol 2001 10 : 11 18.
-
(2001)
Exp Dermatol
, vol.10
, pp. 11-18
-
-
Hanifin, J.M.1
Thurston, M.2
Omoto, M.3
-
21
-
-
19244366008
-
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated
-
Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002 119 : 876 888.
-
(2002)
J Invest Dermatol
, vol.119
, pp. 876-888
-
-
Rappersberger, K.1
Komar, M.2
Ebelin, M.E.3
-
22
-
-
0036677154
-
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug
-
Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002 110 : 277 284.
-
(2002)
J Allergy Clin Immunol
, vol.110
, pp. 277-284
-
-
Kapp, A.1
Papp, K.2
Bingham, A.3
-
23
-
-
0037324145
-
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants
-
Ho V, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003 142 : 155 162.
-
(2003)
J Pediatr
, vol.142
, pp. 155-162
-
-
Ho, V.1
Gupta, A.2
Kaufmann, R.3
|